Section Review: Central & Peripheral Nervous Systems: Selective serotonin reuptake inhibitors in the treatment of depression

References

• TOLLEFSON GD: Selective serotonin reuptake Inhibi- ?tors. In: Textbook of Psychopharmacology. Schatzberg AF, Nemeroff CB (Eds). American Psychiatric Press, Inc., Wash-ington DC (1995).
   Google Scholar
• BOYER WF, FEIGHNER JP: The efficacy of selective sero- Main reuptake inhibitors in depression. In: Selective Serotonin Reuptake Inhibitors. Feighner JP, Boyer WF (Eds). John Wiley & Sons, Chichester, England (1991).
   Google Scholar
• HYTTEL J: Effects of a selective 5-HT inhibitor (Lu 10-171) on rat brain 5-HT turnover. Acta Pharmacol. Toxicol. (1978) 40:439–446.
   Google Scholar
• HYTTEL J: Effect of a specific 5-HT uptake inhibitorcitalopram (Lu 10-171) onr3III-5-HT uptake in rat brain synaptosomes in vitro. Psychopharrnacology (1978) 60:13–18.
   PubMed Web of Science ®Google Scholar
• HY'ITEL J: Citalopram-pharmacological profile of a spe-cific serotonin reuptake inhibitor with antidepressant activity. Prog. Neuropsychopharrnacol. Biol. Psychiat. (1982) 6:277–295.
   Google Scholar
• DUFOUR H, I3OUCHACOURT M, THERMOZ P, VIALA A,ROP PP, GOUEZO F, DURAND A. PETERSEN ITEH: Citalo-pram - a highly selective 5-HT uptake inhibitor in the treatment of depressed patients. fru Clin. Psychopharma-col. (1987) 2:225–237.
   Google Scholar
• OVERO KF: Kinetics of citalopram in man: plasma levelsin patients. Prog. Neuropsychopharmacol. Biol. Psych tat. (1982) 6:311–318.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY SA, RASMUSSEN JGC, LYBY K, CONNOR P, TANG 1105 P: Dose response relationship of citalopram 20 mg, citalopram 40 mg, and placebo in the treatment of moderate and severe depression. Mt. ain. Psychophar-macol. (1992) 6\(Suppl. 5)65–70.
   Google Scholar
• BECH P, CIALDELLA P: Citalopram in depression - meta-analysis of intended and unintended effects. Int. J. Psychopharmacol. (1992) 6\(Suppl. 5).45–54.
   Google Scholar
• SHAW DM, HARRIS B, LLOYD AT, WAHEED W, ROLFE AB,EVANS VM: A comparison of the antidepressant action of eitalopram and amitriptyline. Br. J. Psychiat. (1986) 149:515–517.
   PubMed Web of Science ®Google Scholar
• ANDERSON IM, TOMENSON BM: The efficacy of selectiveserotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol (1994) 8(4).238–249
   PubMed Web of Science ®Google Scholar
• GRAM LF: Fluoxetine. New Engl. J. Med. (1994) 331:1354–1361.
   PubMed Web of Science ®Google Scholar
• SOMMI RW, CRISMON LM, BOWDEN CL: Fluoxetine: aserotonin-specific, second generation antidepressant Psychopharmacotogy (1987) 7:1–15.
   Google Scholar
• KELLY MW, PERRY PJ, HOLSTAD SG, GARVEY MJ: Serumfluoxetine and norfluoxetine concentrations and anti-depressant response. Therapeutic Drug Monitoring (1989) 11:165–170.
   PubMed Web of Science ®Google Scholar
• WERNICKE JF, DUNLOP SR, DORNSEIF BE, ZERBE RL: Fixed dose fluoxetine therapy for depression. Psycho-pharmacol. Bull. (1987) 23:164–168.
   PubMed Web of Science ®Google Scholar
• WERNICKE JF, DUNLOP SR, DORNSEIF BE, BOSOM WORTH JC, HUMBERT M: Low dose fluxoetine therapy for de-pression. Psychopharmacol. Bull. (1988) 24:183–188.
   PubMed Web of Science ®Google Scholar
• CHOUINARD G: A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J. din. Psychiat. (1985) 46:32–37.
   Google Scholar
• STARK P, HARDINSON CD: A review of multicenter con-trolled studies of fluoxetine versus imipramine and placebo in outpatients with major depressive disorders. J. Clin. Psychiat. (1985) 46:53–58.
   PubMed Web of Science ®Google Scholar
• ROOSE SP, GLASSMAN AH, ATTIA E, WOODRING S: Com-parative efficacy of selective serotonin reuptake inhibi-tors and tricyclics in the treatment of melancholia. Am. J. Psychiat. (1994) 151:1735–1739.
   PubMed Web of Science ®Google Scholar
• BENEIELD P, WARD A: Fluvoxamine: a review of its pharrnacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs (1986) 32:313–334.
   PubMed Web of Science ®Google Scholar
• CONTI L, DELL'OSSO LRF, MUSSETTI L, CASSANO GB:Fluvoxamine maleate: double-blind clinical trial versus placebo in hospitalized depressed patients. Curr. Ther. Res. (1988) 43:468–480.
   Web of Science ®Google Scholar
• AMIN MM, ANATH JV, COLEMAN BS, DARCOURT G, FARKAS T, GOLDSTEIN B, LAPIERRE YD, PAYKEL E, WAKE-LIN JS Fluvoirn mine: antidepressant effect confirmed in a placebo-controlled international study. din. Neuro-pharmacol. (1984) 7\(Suppl. 1):317–318.
   Google Scholar
• ROTH D, MAI FES J, SHEENAN ICH, SHEENAN DV: A dou-ble-blind comparison of fluvoxamine, desipramine, and placebo in out-patients with depression. Prog. Neuropsychopbarmacol. Biol. Psychiat. (1990) 14:929–939.
   PubMed Web of Science ®Google Scholar
• OTTEVANGER EA: The efficacy of fluvoxaraine in pa-tients with severe depression. Prog. Neuropsychopbarma-col. Biol. Psychic!. (1994) 18:731–740.
   PubMed Web of Science ®Google Scholar
• KILTS C: Recent pharmacological advances in antide- pressant therapy. Am.J. Med. (1994) 97(Suppl. 6A):3–12.
   Google Scholar
• HEYM J, KOE BK: Pharmacology of sertraline: a review. j. Clin. Psychtat. (1988) 49(Suppl.):40–55.
   Google Scholar
• DOOGAN DP, CAILLARD V: Sertraline: a new antidepres-sant. J. Clin. Psychiat. (1988) 49\(Supp1.8):46–51.
   Google Scholar
• FABRE LF: A double-blind multicenter study comparing the safety and efficacy of sertraline with placebo in major depression. Biol. Psychiat. (1991) 29:353.
   Google Scholar
• REIMHERR FW, CHOUINARD G, COHN CK, COLE JO, ITIL TM, LAPIERRE YD, MASCO HL, MENDELS J: Antidepressant efficacy of sertraline: a double-blind placebo- and amitriptyline-controlled multicenter comparison study In outpatients with major depression. J. Clin. Psych mat. (1990) 51(Suppl. B12):18–27.
   Google Scholar
• AGUGLIA E, CASACCHIA M, CASSANO GB, FARAVELLI C, FERRARI G, GIORDINO P, PANCHERI P, RAVIZZA L, TRABUCHI M, BOLIN° F, SCARPATO A, BERARDI D, PROVENZANO G, BRUGNOLI R, ROZZINI R: Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int. Clin. Psychopharma-col. (1993) 8:197–202.
   PubMed Web of Science ®Google Scholar
• MAGNUSSEN I, TONDER K, ENGBAEK F: Paroxetine, a potent selective long-acting inhibitor of 5-HT uptake in mice. J. Neural Trans. (1982) 55:217–226.
   Web of Science ®Google Scholar
• THOMAS DR, NELSON DR, JOHNSON AM: Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharma-cology (1987) 93:193–200.
   PubMed Web of Science ®Google Scholar
• ICAYE CM, HADDOCK RE, LANGLEY PF, NELSON DR, POPEJA, THOMAS DR et al.: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiat. Scand. (1989) 80(Suppl.):60–75.
   Google Scholar
• HADDOCK RE, JOHNSON AM, LANGLEY PF, NELSON DR, POPE JA, THOMAS DR et al.: Metabolic pathway or paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psy-chiat. Scand. (1989) 80(Suppl.):24–26.
   Google Scholar
• CLAGHORN J: A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients. Int. Clin. Psychopbarmacol. (1992) 6\(Suppl. 4)25–41.
   Google Scholar
• DUNBAR GC, COHN JB, FABRE LF, FEIGHNER JP, FIEVE RR, ME NDELS J, SHRIVASTA Ft.K: A comparison of paroxetine, imipramine, and placebo in depressed outpatients. Br. J. Psychiat. (1991) 159:394–398.
   Google Scholar
• STUPPAECK CH, GERETSEGGER C, WHITWORTH AB, SHUBERT H, PLATZ T, KONIG P, HINTERHUBER H, FLEISH-• HACKER WW: A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpa-tients. J. Clin. Psychopbarmacol. (1994) 14(4):241–246.
   PubMed Web of Science ®Google Scholar
• DEWILDE J, SPIERS R, MERTENS C, BARTHOLOME F,SHOTTE G. LEYMAN 5: A double-blind, comparative, muhicentre study comparing paroxetine with fluoxet-ine in depressed patients. Acta Psychiat. Scand. (1993) 87:141–145.
   Google Scholar
• RICHELSON E: Antidepressants and brain neurochemis- ?try. Mayo Clinic Proc. (1990) 65:1227–1236.
   PubMed Web of Science ®Google Scholar
• ANDREWS JM, NEMEROFF CB: Contemporary manage- mant of depression. Am. J. Med. (1994) 97(Suppl. 6A):24–32.
   Google Scholar
• CREWE HK, LENNARD MS, TUCKER GT, WOODS FR, HAD- DOCK RE: The effect of selective serotonin reuptake inhibitors on cytochrom P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. (1992) 34:262–265.
   PubMed Web of Science ®Google Scholar
• BROSEN K, HANSEN JG, NIELSON KK, SINDRUPS SH, GRAMLF: Inhibition by paroxetine of desipramine metabo-lism in extensive but not in poor metabolizers of sparteine. Eur. J. Clin. Pbarmacol. (1993) 44:349–355.
   PubMed Web of Science ®Google Scholar
• LYDIARD RB, ANTON RF, CUNNINGHAM T: Interactionsbetween sertraline and tricyclic antidepressants [Let-ter]. Am. J. Psychiat. (1993) 150:1125–1126.
   PubMed Web of Science ®Google Scholar
• BERTSCHY G, VANDEL S, FRANCOIS T, BONIN B, BOUGUET S, BAUMAN P, VOLMAT R, SECHTER D, BI-ZOUARD P: Metabolic interaction between tricyclic an-tidepressant and fluvoxamine and fluoxetine, a pharmacogenetic approach. Clin. Neuropbarmacol. (1992) 15\(Suppl. 1 Pt. A):78A–79A.
   Google Scholar
• BROSEN K, SKJELBO E, RASMUSSEN BB, POULSEN HE, LOFT S: Fluvoxanaine as a potent inhibitor of cyto-chrome P4501A2. Biochem. Pharnzacol. (1993) 45:1211–1214.
   PubMed Web of Science ®Google Scholar
• SKJELBO E, BROSEN K: Inhibitions of iraipramine meta-bolism by human liver microsomes. Br.J. Clin. Pharma-col. (1992) 34:256–261.
   PubMed Web of Science ®Google Scholar
• BERTSCHY E, VANDEL S, VANDEL B, ALLERS G, VOLMATR: Fluvoxamine-tricyclic antidepressant interaction: an accidental finding [Letter]. Eur.J. Clin. Pharrnacol. (1991) 40:119–120.
   PubMed Web of Science ®Google Scholar
• STERNBACH H: The serotonin syndrome. Am]. Psychiat.(1991) 148:705–713.
   PubMed Web of Science ®Google Scholar
• DANISH UNIVERSITY AN ELDEPRESSANT GROUP: Citalo-pram:. clinical effect profile in comparison with clomi-pramine: a controlled multicenter study. Psychopharmacology (1986) 90:131–138.
   Google Scholar
• DANISH UNIVERSITY AN FIDEPRESSANT GROUP: Paroxet-ine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effects than clomipramine in a controlled multicenter study. J. Af-fect. Dis. (1986) 90:131–138.
   Google Scholar
• DEVANE CL: Pharmacogenetics and drug metabolism of ••newer antidepressant agents. J. Clin. Psychiat. (1994)55\(Suppl. 12):38–45.
   Google Scholar